https://scholars.lib.ntu.edu.tw/handle/123456789/521075
Title: | The Relationships of Obesity-Related Genetic Variants with Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia | Authors: | Chen P.-Y. Lu M.-L. Huang M.-C. Kao C.-F. PO-HSIU KUO Chiu C.-C. Lin S.-K. HSIU-PO KUO |
Issue Date: | 2015 | Publisher: | Lippincott Williams and Wilkins | Journal Volume: | 35 | Journal Issue: | 5 | Start page/Pages: | 574-578 | Source: | Journal of Clinical Psychopharmacology | Abstract: | Obesity-related genetic variants, including TMEM18 (rs6548238), SH2B1 (rs7498665), and GNPDA2 (rs10938397), have been shown to be associated with obesity in the general population. Our study aimed to test whether these genetic variants are associated with metabolic profiles and metformin treatment response in clozapine-treated schizophrenic patients. We recruited 107 clozapine-treated patients who were genotyped and measured their metabolic profiles. Fifty-five subjects, who had at least 1 metabolic abnormality in a range of measures, were subsequently randomized to a 24-week trial of metformin (n = 28) or placebo (n = 27). We examined the associations between TMEM18, SH2B1, GNPDA2 genetic variants and metabolic profiles at baseline in all patients and metabolic changes in the trial groups. We found a significant association between SH2B1 and blood pressure at baseline in all patients. In the metformin group, TMEM18 minor allele carriers had a greater reduction in insulin levels (P = 0.04). A significantly higher proportion of TMEM18 and GNPDA2 minor allele carriers (60% and 40%) lost more than 7% of their body weight after metformin treatment as compared with their homozygous counterparts (21.7% and 15.4%, P = 0.02 and 0.004, respectively). There were trends toward favorable metabolic changes in minor allele carrier groups. In the placebo group, no association between genetic variants and changes in metabolic profiles was found. In conclusion, the study results suggest that these genes might be associated with metabolic abnormalities and response to metformin in clozapine-treated patients with schizophrenia. ? 2015 Wolters Kluwer Health, Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941282598&doi=10.1097%2fJCP.0000000000000386&partnerID=40&md5=5ed3ad27a5410fc21d14d1c93162aba5 https://scholars.lib.ntu.edu.tw/handle/123456789/521075 |
ISSN: | 0271-0749 | DOI: | 10.1097/JCP.0000000000000386 | SDG/Keyword: | clozapine; insulin; metformin; placebo; clozapine; glucosamine-6-phosphate isomerase; isomerase; membrane protein; metformin; neuroleptic agent; SH2B1 protein, human; signal transducing adaptor protein; TMEM18 protein, human; adult; aged; allele; Article; blood pressure; body weight; controlled study; correlation analysis; double blind procedure; female; gene; genetic association; genetic variability; genotype; GNPDA2 gene; human; insulin blood level; major clinical study; male; metabolic disorder; metabolism; obesity; priority journal; randomized controlled trial; schizophrenia; SH2B1 gene; statistical analysis; TMEM18 gene; treatment response; chemically induced; genetic predisposition; genetic variation; genetics; Metabolic Diseases; middle aged; obesity; schizophrenia; Adaptor Proteins, Signal Transducing; Adult; Aldose-Ketose Isomerases; Alleles; Antipsychotic Agents; Clozapine; Double-Blind Method; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Male; Membrane Proteins; Metabolic Diseases; Metformin; Middle Aged; Obesity; Schizophrenia |
Appears in Collections: | 流行病學與預防醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.